INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Zenas BioPharma, Inc. following a significant drop in stock price after the announcement of Phase 3 trial results for obexelimab [1][3]. Group 1: Company Overview - Zenas BioPharma, Inc. (NASDAQ: ZBIO) is currently under investigation for possible securities fraud [1]. - The company recently announced results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [3]. Group 2: Financial Impact - Following the announcement of the trial results, Zenas's stock price decreased by $17.89 per share, representing a decline of 51.86%, closing at $16.61 per share on January 5, 2026 [3]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].